肺癌筛查六十年:从痰细胞学到低剂量CT及精准时代
本文综述了肺癌筛查从早期胸片和痰细胞学试验到确立低剂量CT(LDCT)为指南推荐干预措施的演变过程。文章回顾了NLST、NELSON等关键随机试验及USPSTF指南修订,早期筛查未显示死亡获益,而LDCT筛查可降低肺癌死亡率。同时探讨了ctDNA分析、AI辅助判读等新兴技术及Lung-RADS对假阳性率的改善作用。
要点
- LDCT筛查较胸片可降低肺癌死亡率,NLST显示肺癌死亡率下降20%,NELSON显示男性下降24%。
- 2021年USPSTF将筛查资格扩大至50-80岁、吸烟≥20包年的人群。
- Lung-RADS已显著降低假阳性率并持续更新,但筛查依从性仍不理想(22-55%)。
核心结论
- LDCT筛查是技术创新、严格临床研究与卫生政策演变的结合,NLST显示肺癌死亡率降低20%,NELSON显示男性降低24%。
- 循环肿瘤DNA分析和AI辅助判读等新兴辅助手段可能提高检测准确性并改善依从性不足的问题。
- Lung-RADS已显著降低假阳性率并持续演进。
研究设计与样本
- 本文为叙述性综述,综合了主要试验文献、指南文件及新兴研究,检索时间为2026年3月至5月。
- 回顾了Mayo Lung Project、Johns Hopkins Lung Project、ALCA CT试验、ELCAP、NLST、NELSON试验及USPSTF指南修订。
关键影像表现/征象
- 日本ALCA试验确立了LDCT可行性,显示93%为I期,而传统方法为53%为I期。
- NLST显示LDCT较胸片使全因死亡率降低6.7%。
诊断标准与关键数值
- NLST显示LDCT较胸片使肺癌死亡率降低20%,全因死亡率降低6.7%。
- NELSON显示男性肺癌死亡率降低24%,女性获益更大。
- 2021年USPSTF修订将筛查资格扩大至50-80岁、吸烟≥20包年。
临床应用与阅片要点
- 早期痰细胞学和胸片筛查试验虽改善早期检出但无死亡获益,日常阅片不应将其作为有效的肺癌筛查手段。
- 筛查依从性仅为22-55%,影像报告中应关注Lung-RADS分类以降低假阳性率并推动规范随访。
- LDCT用于肺癌筛查的指南推荐基于NLST和NELSON等随机对照试验证据,报告时应注明适用人群标准。
局限性
- 本文为叙述性综述而非系统评价,未报告具体检索策略和纳入排除标准。
- 搜索结果截至2026年5月,未纳入后续可能发表的随机对照试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONAL AND OBJECTIVES: To trace the evolution of lung cancer screening from early radiographic and sputum cytology trials through the landmark randomized trials that established low-dose computed tomography (LDCT) as a guideline-endorsed intervention, and to examine emerging technologies poised to transform the field.
MATERIALS AND METHODS: A narrative synthesis of primary trial literature, guideline documents, and emerging research conducted March-May 2026. Key milestones-the Mayo Lung Project, Johns Hopkins Lung Project, Anti-Lung Cancer Association (ALCA) CT trials, Early Lung Cancer Action Project (ELCAP), National Lung Screening Trial (NLST), NELSON trial, and iterative US Preventive Services Task Force (USPSTF) guideline revisions-are reviewed chronologically alongside developments in CT technology and reporting systems.
RESULTS: Early sputum cytology and radiographic trials improved early-stage detection without a mortality benefit. Japanese ALCA trials established LDCT feasibility, demonstrating superior stage distribution (93% vs 53% stage I). The NLST demonstrated a 20% reduction in lung cancer mortality and 6.7% reduction in all-cause mortality with LDCT versus chest radiography, providing the evidence basis for the 2013 USPSTF guidelines. NELSON corroborated these findings, with a 24% lung cancer mortality reduction in men and greater benefit in women. The 2021 USPSTF revision broadened eligibility to ages 50-80 with ≥20 pack-years. Adherence remains suboptimal at 22-55%.
CONCLUSION: LDCT screening represents a convergence of technological innovation, rigorous clinical investigation, and evolving health policy. Emerging adjuncts, including circulating tumor DNA analysis and AI-assisted image interpretation, may improve detection accuracy and address adherence gaps. Lung-RADS has substantially reduced false-positive rates and continues to evolve.
引用
- Raihane, Flesner, Sohail, et al. Sixty Years of Lung Cancer Screening: From Sputum Cytology to Low-Dose CT and the Emerging Precision Era. Acad Radiol. 2026. PMID: 42674935. doi:10.1016/j.acra.2026.08.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。